Aims: The objective was to investigate current situation and risk factors of vancomycin (VAN)-induced acute kidney injury (VI-AKI) in elderly Chinese patients, to assesse the outcomes and its risk factors of patients who developed VI-AKI, in order to provide suggestions for improving the prevention and treatment of VI-AKI in elderly Chinese patients. Method: We retrospectively identified elderly inpatients who received more than 3 doses of VAN therapy. We compared the VI-AKI with NO-AKI patients. The definition of VI-AKI is developing AKI during VAN therapy or within 3 days after withdrawal of VAN. Results: 647 of the 862 elderly inpatients were included. Among those excluded, (89.3%, 192/215) were excluded because of a lack of data on serum creatinine (SCr). Among the included patients, 32.5% (210/647) patients received TDM during VAN therapy. The inadequate TDM rate was 66.9% (424/634) and rate of correct TDM was 3.9% (25/634). 102 patients had confirmed VI-AKI, with an incidence of 15.8% (102/647). Multiple logistic regression analysis revealed that hyperuricemia ([OR]=3.045;p=0.000), mechanical ventilation ([OR]=1.906;p=0.022) and concomitant vasopressor therapy ([OR]=1.919,p=0.027) were independent risk factors for VI-AKI; in addition, serum albumin valley ([OR] =0.885;p=0.000) was determined to be independent protective factor for VI-AKI. Conclusions: The elderly Chinese patients treated with VAN exist the situations below: insufficient monitoring of SCr, inadequate VAN TDM rate and incorrect monitor time. We recommend hospital managers to increase investment in clinical pharmacists to strength professional management. Patients concomitant with hyperuricemia, mechanical ventilation and vasopressor therapy should be paid more attention and a higher serum albumin was more recommend.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.